Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Great Elm Capital Corp. (“GECC”) Schedules Third Quarter 2025 Earnings Release and Conference Call
-
Alps Announces Closing of Business Combination with Globalink Investment Inc.
-
Aspen Group Reports Second Consecutive Quarter of Net Income for First Quarter Fiscal 2026
-
LPL Financial Announces Lower Fees and Streamlined Pricing Across Advisory Platforms
-
Upexi to Participate in Upcoming November Investor Conferences
-
Certara to Participate in Upcoming Investor Conferences
-
Flux Power Announces Pricing of $9.6 Million Underwritten Public Offering
-
FAVO Capital Inc. Announces Corporate Name Change to Stewards Inc.
-
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
-
Getty Images and Perplexity strike multi-year image partnership
-
Abercrombie & Fitch Co. to Report Third Quarter 2025 Results on November 25, 2025
-
Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
-
American Battery Technology Company CEO Ryan Melsert Invited to Present at IEA Energy Innovation Forum 2025, Informing G7 Energy and Environment Ministry Leaders
-
Man Group PLC : Form 8.3 - Spectris plc
-
Man Group PLC : Form 8.3 - American Axle & Manufacturing Holdings, Inc
-
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
-
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
-
RVC Zero Investment LP Announces Investment in Edge Copper Corporation
-
CN Declares Fourth-Quarter 2025 Dividend
-
Northfield and Juno Welcome Historic Webequie-Ontario Partnership Agreement Advancing Critical Ring of Fire Infrastructure
-
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
-
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
-
Birchtree Investments Announces Private Placement Closing
-
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
-
Vireo Growth Inc. to Release Third Quarter 2025 Results on November 12, 2025
-
CN Delivers Strong Third Quarter Financial and Operating Results
-
TappAlpha’s TDAQ Surpasses $25 Million AUM in Under Two Months, Outpacing Nasdaq 100 in Performance
-
Stardust Power Fully Compliant with Nasdaq Listing Requirements
-
Creative Realities, Inc. Announces Third Quarter 2025 Earnings Release Date and Conference Call Information
-
Nasdaq Halts Premium Catering (Holdings) Limited
-
Fenix Outdoor: Quarter 3 report Fenix Outdoor International AG
-
Issue of Equity and Total Voting Rights
-
Acorn, Provider of Monitoring and Control Solutions for Power Generators, Hosts Q3 Earnings Call Thursday Nov. 6th at 11am ET
-
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
-
OROCO RESOURCE CORP. PROVIDES FINANCING UPDATE
-
Taco John’s Offers Free Meals to Support Those Impacted by Shutdown
-
Costamare Inc. Sets the Date for Its Third Quarter 2025 Results Release, Conference Call and Webcast
-
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS
-
Transaction in Own Shares
-
Is the Rental Market finally Cooling? Canada’s Rent Prices Dip as Immigration Slows
-
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
-
Falco Announces Extension of Its Senior Debts
-
BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers
-
September 2025 Quarterly Activities Report
-
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
-
Mesa Air Group enters into an Amendment to its Loan Agreement with the United States Treasury and Provides Update to its Pending Merger with Republic Airways
-
Perspective Therapeutics to Participate in Upcoming November Conferences
-
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorec
-
Upstream Bio to Participate in Upcoming November Investor Conferences
-
Castellum, Inc. Announces the Award of a $66.2 million Full and Open Contract to its SSI Subsidiary
